Roche aims to defend the company’s multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of the Swiss drugmaker’s $4 billion-per-year Ocrevus product and advanced trials of the experimental medicine fenebrutinib.

Novartis announced that the Phase III COMBI-I trial of the company’s experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to hit the primary endpoint in melanoma.

Several studies suggest that even mild cases of Covid-19 stimulate lasting immune responses, not only in disease-fighting antibodies, but in B-cells and T-cells.

The U.S. Food and Drug Administration approved Novartis’ Kesimpta (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis in adults.

Sanofi is rumored to have a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies, including South San Francisco-based Principia Biopharma.

One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO 2020.

A look at upcoming PDUFA dates for the U.S. Food and Drug Administration, including Viela Bio’s inebilizumab for NMOSD.

The immuno-oncology therapy CAR-T utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.

Top 10 Pipelines To Watch: 2019 Annual Report

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Eli Lilly and Company and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo for $235.00 per share in cash, or approximately $8.0 billion.